Robert Schwarcz

This inventor holds 20 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: University System of Maryland, Pharmacia & Upjohn, Astra Aktiebolag. Active years: 1984-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Schwarcz. Retrieved from https://idiyas.com/inventor/robert-schwarcz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 2)

% Patents Active = 95.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 4.5

ph-index = 5

Forward Citations = 61(Granted Patents)

Company Filing History:

14 out of 2,029

University System of Maryland

Merrell Dow Pharmaceuticals

patents

5. 2 out of 91

The J. David Gladstone Institutes

patents

6. 2 out of 22

The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Gladstone

patents

7. 2 out of 2

Universita Delgi Studi Di Parma

Merrell Pharmaceuticals, Inc.

patents

11. 1 out of 220

Pharmacia Corporation

patents

12. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1984-2016

Loading Chart...

Areas of Expertise:

Small Molecule Inhibitors

Kynurenine-3-Monooxygenase

3-Hydroxyanthranilate

Recombinant KAT Enzyme

Nicotinic Acid Derivatives

Anthranilic Acid Derivatives

NMDA Antagonists

Amino Acid Isomers

Substituted Kynurenines

Medicinal Use

Enzyme Inhibitors

Compounds

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9487486 - Derivatives of nicotinic acid N-oxide, their preparation and their use as inhibitors of enzyme 3-hydroxyanthranilate-3, 4-dioxygenase (2016-11-08),

2. 9260394 - Derivatives of nicotinic acid N-oxide, their preparation and their use as inhibitors of enzyme 3-hydroxyanthranilate-3, 4-dioxygenase (2016-02-16),

3. 8710237 - Small molecule inhibitors of kynurenine-3-monooxygenase (2014-04-29),

4. 8466182 - Small molecule inhibitors of kynurenine-3-monooxygenase (2013-06-18),

5. 8071631 - Small molecule inhibitors of kynurenine-3-monooxygenase (2011-12-06),

6. 7994338 - Small molecule inhibitors of kynurenine-3-monooxygenase (2011-08-09),

7. 6136572 - Recombinant KAT enzyme and process for its preparation (2000-10-24),

8. 5883129 - Hydroxylated anthranilic acid derivatives (1999-03-16),

9. 5817496 - Recombinant kat enzyme from rat (1998-10-06),

10. 5786508 - Substituted kynurenines and process for their preparation (1998-07-28),

11. 5708030 - Substituted kynurenines and process for their preparation (1998-01-13),

12. 5688945 - Compounds (1997-11-18),

13. 5661183 - 3-hydroxy anthanilic acid derivatives (1997-08-26),

14. 5547991 - NMDA antagonism method (1996-08-20),

15. 5523475 - New compounds (1996-06-04),

Title: Innovations of Robert Schwarcz: A Spotlight on His Patents and Contributions

Introduction

Robert Schwarcz, based in Baltimore, MD, is a notable inventor recognized for his significant contributions to the field of biochemistry and pharmacology. With a remarkable portfolio consisting of 20 patents, he has made strides in developing innovative compounds with potential therapeutic applications.

Latest Patents

Among his latest work, Schwarcz has developed unique derivatives of nicotinic acid N-oxide. These compounds are characterized by their ability to inhibit the enzyme 3-hydroxyanthranilate-3, 4-dioxygenase (3HAO). This inhibition is crucial as it aids in reducing QUIN biosynthesis in vivo, particularly under excitotoxic or pathological conditions. Notably, these derivatives are chemically stable against auto-oxidation, showcasing their potential as viable pharmaceutical agents.

Career Highlights

Robert Schwarcz has had an impactful career, particularly during his tenure at the University of Maryland, Baltimore, and Pharmacia & Upjohn S.p.a. His research has substantially advanced our understanding of neurochemistry and its related disorders, earning him recognition in the scientific community.

Collaborations

Throughout his career, Schwarcz has collaborated with esteemed colleagues such as Carmela Speciale and Paul J Muchowski. These collaborations have facilitated the exchange of ideas and fostered advancements in their collective research, further enhancing the impact of their findings.

Conclusion

Robert Schwarcz exemplifies the spirit of innovation in the field of biochemistry. His extensive patent portfolio and collaborations mark him as a key contributor to ongoing research aimed at therapeutic solutions for neurological conditions. As new discoveries emerge, Schwarcz's work will undoubtedly continue to influence future innovations in medical science.

Profile summary based on public USPTO records.